An observational study in Alzheimer Disease, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 6 sites in Germany. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Heinrich-Heine University, Duesseldorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Alzheimer Disease with a site in Germany — 26 open to participants now, 39 under way, 17 of them phase 3. Alzheimer Disease · Germany.
Among the 213 studies in Alzheimer Disease with a site in Germany, this one is the 14th largest by planned enrollment of the 20 observational ones that give a count, is one of 14 that started in 2025, is one of 20 observational ones, reaches primary completion later than 17 of the 38 other live ones, and was the 186th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →26 of the 213 studies in Alzheimer Disease with a site in Germany are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Germany, United States, Australia and 2 more countries
Ages 50–90
Sanofi · Sites in Germany, United States, Australia and 4 more countries
Ages 55–85
Exciva GmbH · Sites in Germany, United States, Canada and 6 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 23 more countries
Ages 55–90
Technical University of Munich · Sites in Germany
Ages 18+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 74 · Phase 3 87 · Phase 4 5
First in 2002; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 356 across the 193 interventional studies, 170 across the 20 observational. Of the 162 that completed or were terminated, 79 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 213 have an industry lead sponsor. The 10 most frequent:
Heinrich-Heine University, Duesseldorf is the lead sponsor of 180 studies on the registry; 54 are open to participants now.
Heinrich-Heine University, Duesseldorf has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Alzheimer Disease with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06544616Janssen Pharmaceutica N.V., BelgiumA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | 2026-12-22 |
| NCT07212699Technical University of MunichDevelopment of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 213 studies in Alzheimer Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores. Adverse effects and adverse events without a clear causal relationship will be documented in terms of frequency and severity. Furthermore, the progression of improvement in Alzheimer's symptoms as a result of TPS treatment is summarized in various neuropsychological scales.
AD Patients undergoing TPS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
i. Age = 18 to 85 ii. N>=100, clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the as a screening tool) and impairment of activities of daily living for more than six months iii. MRI scan, in vivo evidence from CSF and/or PET using the NIA-AA criteria, which categorize the underlying pathological processes based on biomarkers, should be added if possible, but are optional. These biomarkers are categorized as ß-amyloid deposition, pathological tau and neurodegeneration [AT(N)], which can be detected on imaging and in biofluids. If possible, patients with Alzheimer's disease (AD) or Alzheimer's continuum should be included.
iv. TPS treatment in a center of a neurological or psychiatric specialist and performed under supervision of a specialist
Exclusion Criteria:
i. Relevant intracerebral pathologies not related to Alzheimer's disease, such as vascular encephalopathy Fazekas grade 3, tumors, vascular malformations, pregnancy, metal implants, CAA according to Boston criteria, Z.n. or during antibody therapy ii. Blood coagulation disorders or oral anticoagulation iii. Epilepsy iv. Medical conditions leading to non-compliance with the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months that have planned treatment with TPS
Diagnostic Test: Registry
Clinical data collection of patients scheduled for on-label treatment
Number of (Serious) Adverse Events
Number of adverse events (without causal relationship to therapy) AE, SAE (query after the first 6-cycle block and before each booster) scaling according to NRS (1-10) for each ADE (query before each stimulation)
Time frame: through study completion, an average of 1 year
Number of adverse device effects
Number of ADEs and (U)SADEs scaling according to NRS (1-10) for each ADE (query before each stimulation)
Time frame: through study completion, an average of 1 year
ADAS
Alzheimer's Disease Asessment Scale (ADAS) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)
Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months
Mini Mental State Examination (MMSE) baseline and follow- up
Mini Mental State Examination (MMSE) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)
Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months
BDI-II
BDI-II baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)
Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months
Clinical Dementia Rating Sum of Boxes Score (CDR-SB)
Clinical Dementia Rating Sum of Boxes Score (CDR-SB) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)
Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months
Alzheimer's Disease Cooperative Study/ Activities of Daily Living Scale (ADCS-ADL)
Alzheimer's Disease Cooperative Study/ Activities of Daily Living Scale (ADCS-ADL) at baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation)
Time frame: Baseline, post first 6 sessions and after 3, 6, 9 and 12 months
Numeric Rating Scale (NRS) for the main symptom
Numeric Rating Scale (NRS) for the main symptom
Time frame: 12 months
Not enrolling at this site.
Started Aug 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 25 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heinrich-Heine University, Duesseldorf →